Aphton Corp., of Miami, said the U.S. patent office allowed a new patent titled "Immunogens Against Gonadotropin Releasing Hormone." The patent covers Aphton's immunogens for neutralizing the key reproductive hormone gonadotropin releasing hormone called GnRH.
Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it received its first two patents in Europe and Japan covering key components of its gene regulation technologies for pharmaceutical control of a broad range of cellular processes. The patents cover novel genes that encode specialized proteins that bind selectively to Ariad's small-molecule drugs and control cellular activity through regulated gene transcription and protein secretion.
Copernicus Therapeutics Inc., of Cleveland, said Case Western Reserve University was issued U.S. Patent No. 6,072,041, which covers a novel fusion protein technology that delivers proteins to the luminal surface of epithelial cells. The protein consists of a single chain antibody fragment that targets any transcytotic receptor and any protein payload. Copernicus has an exclusive license to this.
Cortex Pharmaceuticals Inc., of Irvine, Calif., said it received notices of allowance on three patent applications, one from the Mexican patent office for the patent titled "Drugs That Enhance Synaptic Responses Mediated by AMPA Receptors," and two from the U.S. patent office regarding "Treatment of Schizophrenia with Ampakines and Neuroleptics," and "Acylbenzoxazines for Enhancing Synaptic Response."
Cybergenetics, of Pittsburgh, was awarded U.S. Patent No. 6,054,268 for its lane tracking innovations in automated DNA fragment analysis. The patent broadly protects automated lane tracking functionality, and includes claims on genes discovered via such automation.